AI-generated analysis. Always verify with the original filing.
Sigyn Therapeutics, Inc. entered into a one-year Convertible Note Purchase Agreement on February 12, 2026, constituting a material definitive agreement and involving an unregistered sale of securities. The agreement is detailed in Exhibit 99.1.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry Into a Material Definitive Agreements On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agr
Unregistered Sale of Securities . See Item 1.01. ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits Exhibit No. Title 99.1 Convertible Note Purchase Agre